This inventor holds 8 USPTO granted patents and 2 published patent applications and 3 EPO patents. Top assignee: Yamaguchi University. Active years: 2016-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2016-2025
Title: Kazuhiro Kimura: Innovator in Retinochoroidal Disorder Treatments
Introduction
Kazuhiro Kimura is a prominent inventor based in Yamaguchi, Japan. He has made significant contributions to the field of medical science, particularly in the treatment of retinochoroidal disorders. With a total of eight patents to his name, Kimura's work is recognized for its innovative approach to addressing complex medical issues.
Latest Patents
One of Kimura's latest patents focuses on an inhibitor for retinochoroidal disorders. This invention aims to provide a solution for retinochoroidal scar formation and atrophy in various retinal tissues. The active ingredient in this inhibitor is (E)-4-(2-{3-[(1H-pyrazol-1-yl)methyl]-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-yl}vinyl)benzoic acid, along with its esters or salts. This innovative treatment can inhibit collagen atrophy in retinal pigment epithelium cells, fibroblasts, and glial cells, thereby addressing retinochoroidal disorders effectively.
Career Highlights
Kazuhiro Kimura is affiliated with Yamaguchi University, where he conducts research and develops his inventions. His work has garnered attention in the medical community, particularly for its potential to improve the quality of life for individuals suffering from retinal disorders. His dedication to research and innovation has positioned him as a key figure in his field.
Collaborations
[This section has been skipped due to space constraints.]
Conclusion
Kazuhiro Kimura's contributions to the field of retinochoroidal disorder treatments highlight his innovative spirit and commitment to medical advancement. His patents reflect a deep understanding of complex medical challenges and a desire to improve patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile